MiR-590-5p promotes cisplatin resistance via targeting hMSH2 in ovarian cancer

被引：0
作者：
Bing Li
Xuejie Xu
Linlin Zheng
Xiaojie Jiang
Jing Lin
Guoliang Zhang
机构：
[1] the Affiliated Hospital of Putian University,Department of Medical Oncology
[2] the Affiliated Hospital of Putian University,Department of Hepatobiliary Surgery
[3] the Affiliated Hospital of Putian University,Department of Pathology
[4] the Affiliated Hospital of Putian University,Department of Thyroid Surgery
来源：
Molecular Biology Reports | 2023年 / 50卷
关键词：
Ovarian cancer; hMSH2; miR-590-5p; Cisplatin resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：6819 / 6827
页数：8
相关论文
共 52 条
  • [1] Lheureux S(2019)Epithelial ovarian cancer: evolution of management in the era of precision medicine CA Cancer J Clin 69 280-304
  • [2] Braunstein M(2014)Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? Gynecol Oncol 133 624-631
  • [3] Oza AM(2012)Molecular mechanisms of cisplatin resistance Oncogene 31 1869-1883
  • [4] Davis A(1991)DNA unwinding produced by site-specific intrastrand cross-links of the antitumor drug cis-diamminedichloroplatinum(II) Biochemistry 30 8026-8035
  • [5] Tinker AV(2016)DNA mismatch repair and the DNA damage response DNA Repair (Amst) 38 94-101
  • [6] Friedlander M(2008)Platinum resistance: the role of DNA repair pathways Clin Cancer Res 14 1291-1295
  • [7] Galluzzi L(1998)The role of DNA mismatch repair in drug resistance Clin Cancer Res 4 1-6
  • [8] Bellon SF(2000)Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy Clin Cancer Res 6 1415-1421
  • [9] Coleman JH(2001)The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis Cancer Res 61 7369-7374
  • [10] Lippard SJ(1994)Purified human MSH2 protein binds to DNA containing mismatched nucleotides Cancer Res 54 5539-5542
123456